An autoimmune component has been long suspected in narcolepsy, leading in the mid-1980s to a Japanese study which associated narcolepsy with a specific immune system marker.

In a 1998 breakthrough, narcolepsy was tied to the loss of brain cells located in the hypothalamus that produce the hypocretin neurotransmitters, further implicating the immune system.

This latest discovery moves us closer to understanding what causes this cell destruction.

The article, “Narcolepsy is strongly associated with the T-cell receptor alpha locus,” published in Nature Genetics earlier this week, details the work of a prestigious team of international researchers led by Emmanuel Mignot, MD PhD, Director of Stanford University’s Center for Narcolepsy and Chair of Narcolepsy Network’s Medical Advisory Board. “At last, we now know for sure narcolepsy involves the immune system,” Dr. Mignot says.

Through research spanning several continents and involving three distinct ethnic groups, a tight association has now been found between narcolepsy and a genetic mutation in the “T-cell receptor alpha locus,” a region on human chromosome 14. T-cells are the immune system’s vehicle for identifying and attacking foreign bodies such as bacteria and viruses. In an auto-immune disorder, these cells may mistakenly attack the body’s own cells. Further research is needed to determine the precise role of this mutation in the development of narcolepsy.

Narcolepsy is an often misunderstood and debilitating sleep disorder characterized by excessive daytime sleepiness, overpowering sleep attacks and fragmented nighttime sleep. It also includes the REM-related symptoms of cataplexy – a loss of muscle tone triggered by sudden emotional stimuli, which is unique to narcolepsy – and hallucinations and/or sleep paralysis upon falling asleep and/or waking. Symptoms vary in number and severity from one person to another, as does response to available treatments. For some, narcolepsy is mildly inconvenient. For others, it can be disabling.

People with narcolepsy greet each new development with renewed hope for the future.

The first-line medications for treating the symptoms of narcolepsy (Provigil and Xyrem) have only become available within the past decade or so. While they have significantly improved the quality of life for many, patients may still experience limiting residual symptoms. As awareness of narcolepsy grows both in the public arena and within the medical community, time to diagnosis is decreasing. As a result, the narcolepsy patient population includes an increasingly higher percentage of children, adolescents and young adults. Patricia Duffin Higgins, RN, President of Narcolepsy Network, says “It is especially for these young people that we must keep alive hope for the development of more effective treatment options and if not a cure, at least the ability to identify those at risk for developing narcolepsy and the means to prevent it in future generations. Dr Mignot gives us that hope: This [latest finding] is opening the door for preventive therapies.”

“People with narcolepsy are so very fortunate to have cutting-edge researchers committed to solving the mysteries of our disorder. It is no surprise to us that this latest finding provides a new and novel model for research in over 100 other unsolved immune-related disorders,” Higgins states. Narcolepsy Network strongly encourages its members to participate in research studies and has facilitated several events over the past two years at which participants were able to donate blood for this and other DNA studies.

Narcolepsy Network is a non-profit patient support organization representing all Americans with narcolepsy as well as the less common diagnosis of idiopathic hypersomnia (excessive sleepiness of unknown origin). Narcolepsy is a life-long disorder, with symptoms usually presenting in adolescence, and diagnosis often delayed until the second or third decade. Even with treatment, narcolepsy limits patients in many all aspects of life.

- – - -

CONTACT: Eveline Honig, MD MPH

Executive Director

Narcolepsy Network

914-741-5680

ehonig@narcolepsynetwork.org

“I was conscious, but I couldn’t move,” remembers the mum-of-three. “The one bonus was that the entire Cambridge United squad were in there, back in the days when Dion Dublin was on the team.

They waited with me until the ambulance came: all the other girls were jealous!”

The collapse was, explains Louise, a symptom of narcolepsy – a rare and chronic sleep disorder. Affecting an estimated five in every 10,000 people, it’s a neurological condition which causes a wide range of disabling symptoms (everything from extreme fatigue to cataplexy, sudden loss of muscle control).

Diagnosed when she was just 19, Louise has battled narcolepsy all her adult life.

She relies on daily amphetamines – between six and eight tablets a day – to keep her going. And there is no cure.

“You learn to live with these things,” explains Louise, 39. “You have to really, don’t you? And I always said I wouldn’t let narcolepsy get the better of me.

“You have to live your life and make the most of every day. And I’ve got lots to be grateful for – like my three lovely sons.”

Louise first showed signs of narcolepsy in her mid to late teens. Fidgety at school, she admits it was hard to concentrate in class. And, exhausted, she often spent most of the weekend in bed. By the time she got her first job, aged 17, Louise was feeling drowsy almost all the time; as soon as she got home at night, she’d be out like a light.

“Sometimes I’d go to bed on a Friday and literally couldn’t get out of bed all weekend,” she remembers. “My parents would say ‘How can you be so lazy?’ – they got really cross. I lost friends over it too:

when they came to collect me for a night out I was never ready, because I’d have fallen asleep on my bed. “And I noticed that, when I was at work, my writing sometimes started to trail off; it looked like a child’s writing. I knew there was something wrong. And I wasn’t going to give up until I’d found out what it was.”

Referred to Addenbrooke’s, Louise was tested for all kinds of things, from anaemia to hormone imbalance. But, for a whole year and a half, doctors couldn’t get to the bottom of her problems. “You start to think you’re being a div, that you’re going barmy,” admits Louise.

It wasn’t until she had her first cataplexic episode – when her mouth began to twitch uncontrollably – that everyone began to take Louise seriously.

“My mum actually thought I was having a stroke,” she adds.

Then, after a consultation with a student doctor, narcolepsy was diagnosed.

“They did a tissue typing test which confirmed it,” Louise explains. “It was a bit scary; I’d never even heard of this thing. But, more than anything, it was a relief – a relief to finally know what was wrong.”

Sent to a London hospital, for a further two weeks of tests, Louise then started medication: first a herbal caffeine supplement and then, when that failed, amphetamines – the primary ingredient in Ecstasy. “I’ve been taking them for 20 years now,” she says. “They’re Class A drugs, basically. But they enable me to live a normal life.”

Taking up to eight amphetamines a day means the Cambridge mum is awake – and on the go – from dawn until dusk. There are, she says, certain side-effects, such as early morning palpitations. But without the pills, Louise would struggle to keep her eyes open.

When the drugs wear off, in the evening, she becomes instantly drowsy. “Who else do you know that falls asleep eating their dinner?” asks Louise, laughing. “My head just drops and I end up with my chin in gravy or tomato sauce . . .

“While the kids are awake, I’m awake. I manage by being constantly on the go: I can’t sit down to watch telly, not even EastEnders, because I just fall asleep. So I do the cleaning, do a bit of decorating . . .

“The sad thing is that whenever I do get time to myself I can’t enjoy it – I’m asleep.

I can’t have a nice hot bath, or paint my nails, or call my friends on the phone in the evening. The last time I went to the cinema was when I was 15.”

Louise says her health was at its worst when Aaron, her eldest son, was tiny.

Living alone, a young single mum, her drug regime wasn’t working properly; suffering from exhaustion, she developed what she describes as “automatic behaviour”.

Absentmindedly, she did all kinds of things – from putting laundry in the freezer to, on one memorable occasion, drinking bleach. “I burned my mouth, it was horrible,” she remembers. “That was quite scary.”

Since then, medication has helped bring Louise’s condition under far better control. And Aaron, now 15, is, she says, a great source of support. “When I nod off over dinner he’ll wake me up,” laughs Louise.

Louise went on to have two more boys with her current partner: Lee, eight, and Jay, two. She had to stay on her meds throughout all her pregnancies which was, she admits, a real worry; after two decades on amphetamines, Louise says she could be at risk of an enlarged heart herself (and has just had a scan which, thankfully, pronounced her fit and well).

“Without the pills I wouldn’t be able to function really,” continues Louise. “I wouldn’t be able to look after the kids, because I wouldn’t be able to stay awake.”

Lee has ADHD (attention defecit and hyperactivity disorder), meaning he has behavioural problems and is always incredibly active. It’s a challenge for any mum; for Louise it can be totally debilitating.

Thanks to her medication, Louise can drive. But she refuses to get behind the wheel in the evening, because that’s when her pills wear off – and the inevitable drowsiness kicks in. “I know what could happen,” adds Louise. “And there is no way I’d put my kids and other people at risk.”

As well as taking the pills, Louise has learned to manage her condition, within reason, herself. She steers clear of warm, dark environments, which are more likely to lull her to sleep.

And she can pretty much control the cataplexy, which is triggered by emotions, such as anger or amusement. As soon as Louise detects an attack (usually thanks to a tingling sensation) she removes herself from the source of the emotion – and mentally calms herself down.

Although she had to quit work in her early 20s because of her illness, Louise has always been keen to do voluntary jobs:

until a couple of years ago, she was city councillor for King’s Hedges.

“I am proud of that,” she adds. “But I’m a real believer in getting on with things.

Either you get out there and live your life, or you spend it sitting on the sidelines.”

http://www.cambridge-news.co.uk

The gene has a known role in the immune system, which strongly suggests that autoimmunity, in which the immune system turns against the body’s own tissues, plays an important role in the disorder.

“The link between narcolepsy and autoimmunity was proposed decades ago, but efforts to verify it have failed repeatedly.

Current findings leave little doubt that autoimmunity plays a role,” says Merrill Mitler, Ph.D., a program director with the National Institute of Neurological Disorders and Stroke (NINDS).

The study was funded principally by NINDS, with additional support from the National Institute of Mental Health (NIMH), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID), all components of NIH.

The new study, which appears today in Nature Genetics, focused on narcolepsy with cataplexy – a sudden loss of muscle tone that can cause a person to collapse, with or without falling asleep.

About 1 in 2,000 Americans have narcolepsy-cataplexy. The symptoms of narcolepsy-cataplexy have been shown to result from the death of a small group of brain cells that normally regulate the sleep-wake cycle by releasing chemicals called hypocretins.

Genetic and environmental factors both clearly play a role in narcolepsy-cataplexy. Until now, the best evidence for autoimmunity as a cause of the disorder was the discovery that nearly everyone with the disorder has unique variants of a gene called HLA-DQB1*0602. This is one of the genes that encodes HLA proteins, which dot the surface of the body’s cells and help the immune system identify foreign proteins. Some researchers theorize that the HLA variants found in people with narcolepsy-cataplexy predispose them to an autoimmune reaction that destroys their hypocretin-producing cells.

There are gaps in that theory, however, says Emmanuel Mignot, M.D., Ph.D., director of the Center for Narcolepsy at Stanford University School of Medicine in Palo Alto, Calif., and a Howard Hughes Medical Institute investigator. Dr. Mignot discovered the link between narcolepsy and the hypocretins, and helped establish the link to the HLA system. HLA proteins are found in many tissues including the brain, where they may affect brain development, he says.

HLA variations, however, do not fully account for narcolepsy-cataplexy. Dr. Mignot led a genome-wide association study to search for other genes associated with narcolepsy-cataplexy. These studies involve scanning the genome – the entire set of DNA – for small differences between people who have a disorder and people who do not. Dr. Mignot’s study included more than 4,000 individuals, all of whom had the HLA variants that predispose to narcolepsy-cataplexy but only about half of whom had the disorder. Participants were recruited so that many genetic groups were represented. Subjects were from the United States and eight countries in Europe and Asia; hundreds were African-American, Korean, and Japanese, groups known to have a high incidence of the disorder.

The researchers discovered that in addition to unique HLA variants, people with narcolepsy-cataplexy are also more likely to have unique variants of the TCRA gene, which encodes a receptor protein on the surface of T cells. T cells are the mobile infantry of the immune system. In concert with the HLA proteins, the T cell receptor enables T cells to recognize and attack foreign invaders, such as bacteria and viruses. Changes to the T cell receptor could increase the likelihood that the cells will direct their attack against the body.

The findings of Dr. Mignot’s group indicate that narcolepsy-cataplexy is linked to autoimmunity and involves T-cells. The research could lead to new approaches to prevention and treatment. One possibility may be preventing the disorder by stopping the effects of the autoimmune process. “If we can define the changes in the T cell receptor associated with narcolepsy-cataplexy, we might be able to develop drugs that block the protein’s abnormal activity and prevent the onset of the disorder,” says Dr. Mignot. Current treatments such as stimulant drugs for combating daytime sleepiness and antidepressants for cataplexy are only able to control symptoms, and do not address the underlying loss of hypocretin cells.

It is important to note that this study, like most genome-wide association studies, did not identify genetic variants that directly cause narcolepsy-cataplexy. Instead it identifies groups that are more likely to show narcolepsy-cataplexy and groups that are less likely to show the disorder. In people with the HLA variants that predispose to narcolepsy-cataplexy, there is about a 20-fold higher frequency of the disorder if variants in the TCRA gene are present. It is yet to be known which people with the genetic variants will go on to develop narcolepsy-cataplexy.

Other risk factors for narcolepsy-cataplexy remain to be discovered, and Dr. Mignot’s findings could provide clues to their identity. For example, further studies to characterize the T cells in people with narcolepsy-cataplexy could help reveal whether specific environmental factors – such as infections – contribute to the disorder. Dr. Mignot’s findings also could lead to a better understanding of other autoimmune diseases where HLA genes are known to play a role, such as multiple sclerosis and type 1 diabetes.

http://www.hindu.com/

As a history major, Alex wrote about a dozen papers a semester. He also ran a student organization, for which he often worked more than forty hours a week; when he wasn’t on the job, he had classes.

Weeknights were devoted to all the schoolwork that he couldn’t finish during the day, and weekend nights were spent drinking with friends and going to dance parties. “Trite as it sounds,” he told me, it seemed important to “maybe appreciate my own youth.” Since, in essence, this life was impossible, Alex began taking Adderall to make it possible.

Adderall, a stimulant composed of mixed amphetamine salts, is commonly prescribed for children and adults who have been given a diagnosis of attention-deficit hyperactivity disorder.

But in recent years Adderall and Ritalin, another stimulant, have been adopted as cognitive enhancers: drugs that high-functioning, overcommitted people take to become higher-functioning and more overcommitted. (Such use is “off label,” meaning that it does not have the approval of either the drug’s manufacturer or the Food and Drug Administration.)

College campuses have become laboratories for experimentation with neuroenhancement, and Alex was an ingenious experimenter.

His brother had received a diagnosis of A.D.H.D., and in his freshman year Alex obtained an Adderall prescription for himself by describing to a doctor symptoms that he knew were typical of the disorder.

During his college years, Alex took fifteen milligrams of Adderall most evenings, usually after dinner, guaranteeing that he would maintain intense focus while losing “any ability to sleep for approximately eight to ten hours.” In his sophomore year, he persuaded the doctor to add a thirty-milligram “extended release” capsule to his daily regimen.

Alex recalled one week during his junior year when he had four term papers due. Minutes after waking on Monday morning, around seven-thirty, he swallowed some “immediate release” Adderall.

The drug, along with a steady stream of caffeine, helped him to concentrate during classes and meetings, but he noticed some odd effects; at a morning tutorial, he explained to me in an e-mail, “I alternated between speaking too quickly and thoroughly on some subjects and feeling awkwardly quiet during other points of the discussion.”

Lunch was a blur: “It’s always hard to eat much when on Adderall.” That afternoon, he went to the library, where he spent “too much time researching a paper rather than actually writing it—a problem, I can assure you, that is common to all intellectually curious students on stimulants.”

At eight, he attended a two-hour meeting “with a group focussed on student mental-health issues.” Alex then “took an extended-release Adderall” and worked productively on the paper all night. At eight the next morning, he attended a meeting of his organization; he felt like “a zombie,” but “was there to insure that the semester’s work didn’t go to waste.” After that, Alex explained, “I went back to my room to take advantage of my tired body.” He fell asleep until noon, waking “in time to polish my first paper and hand it in.”

I met Alex one evening last summer, at an appealingly scruffy bar in the New England city where he lives.

Skinny and bearded, and wearing faded hipster jeans, he looked like the lead singer in an indie band. He was ingratiating and articulate, and smoked cigarettes with an ironic air of defiance.

Alex was happy enough to talk about his frequent use of Adderall at Harvard, but he didn’t want to see his name in print; he’s involved with an Internet start-up, and worried that potential investors might disapprove of his habit.

After we had ordered beers, he said, “One of the most impressive features of being a student is how aware you are of a twenty-four-hour work cycle. When you conceive of what you have to do for school, it’s not in terms of nine to five but in terms of what you can physically do in a week while still achieving a variety of goals in a variety of realms—social, romantic, sexual, extracurricular, résumé-building, academic commitments.”

Alex was eager to dispel the notion that students who took Adderall were “academic automatons who are using it in order to be first in their class, or in order to be an obvious admit to law school or the first accepted at a consulting firm.”

In fact, he said, “it’s often people”—mainly guys—“who are looking in some way to compensate for activities that are detrimental to their performance.” He explained, “At Harvard, at least, most people are to some degree realistic about it. . . . I don’t think people who take Adderall are aiming to be the top person in the class. I think they’re aiming to be among the best. Or maybe not even among the best. At the most basic level, they aim to do better than they would have otherwise.”

He went on, “Everyone is aware of the fact that if you were up at 3 A.M. writing this paper it isn’t going to be as good as it could have been. The fact that you were partying all weekend, or spent the last week being high, watching ‘Lost’—that’s going to take a toll.”

Alex’s sense of who uses stimulants for so-called “nonmedical” purposes is borne out by two dozen or so scientific studies.

In 2005, a team led by Sean Esteban McCabe, a professor at the University of Michigan’s Substance Abuse Research Center, reported that in the previous year 4.1 per cent of American undergraduates had taken prescription stimulants for off-label use; at one school, the figure was twenty-five per cent. Other researchers have found even higher rates: a 2002 study at a small college found that more than thirty-five per cent of the students had used prescription stimulants non-medically in the previous year.

Drugs such as Adderall can cause nervousness, headaches, sleeplessness, and decreased appetite, among other side effects. An F.D.A. warning on Adderall’s label notes that “amphetamines have a high potential for abuse” and can lead to dependence. (The label also mentions that adults using Adderall have reported serious cardiac problems, though the role of the drug in those cases is unknown.)

Yet college students tend to consider Adderall and Ritalin benign, in part because they are likely to know peers who have taken the drugs since childhood for A.D.H.D. Indeed, McCabe reports, most students who use stimulants for cognitive enhancement obtain them from an acquaintance with a prescription. Usually, the pills are given away, but some students sell them.

According to McCabe’s research team, white male undergraduates at highly competitive schools—especially in the Northeast—are the most frequent collegiate users of neuroenhancers.

Users are also more likely to belong to a fraternity or a sorority, and to have a G.P.A. of 3.0 or lower. They are ten times as likely to report that they have smoked marijuana in the past year, and twenty times as likely to say that they have used cocaine. In other words, they are decent students at schools where, to be a great student, you have to give up a lot more partying than they’re willing to give up.

The BoredAt Web sites—which allow college students to chat idly while they’re ostensibly studying—are filled with messages about Adderall.

Posts like these, from the BoredAtPenn site, are typical: “I have some Adderall—I’m sitting by room 101.10 in a grey shirt and headphones”; “I have Adderall for sale 20mg for $15”; “I took Adderall at 8 p.m., it’s 6:30 a.m. and I’ve barely blinked.”

On the Columbia site, a poster with an e-mail address from CUNY complains that her friends take Adderall “like candy,” adding, “I don’t want to be at a disadvantage to everyone else. Is it really that dangerous? Will it fuck me up?

My grades weren’t that great this year and I could do with a bump.” A Columbia student responds, “It’s probably not a good idea if you’re not prescribed,” but offers practical advice anyway: “Keep the dose normal and don’t grind them up or snort them.” Occasional dissents (“I think there should be random drug testing at every exam”) are drowned out by testimonials like this one, from the BoredAtHarvard site: “I don’t want to be a pusher or start people on something bad, but Adderall is AMAZING.”

Alex remains enthusiastic about Adderall, but he also has a slightly jaundiced critique of it.

“It only works as a cognitive enhancer insofar as you are dedicated to accomplishing the task at hand,” he said. “The number of times I’ve taken Adderall late at night and decided that, rather than starting my paper, hey, I’ll organize my entire music library!

I’ve seen people obsessively cleaning their rooms on it.” Alex thought that generally the drug helped him to bear down on his work, but it also tended to produce writing with a characteristic flaw.

“Often, I’ve looked back at papers I’ve written on Adderall, and they’re verbose. They’re belaboring a point, trying to create this airtight argument, when if you just got to your point in a more direct manner it would be stronger. But with Adderall I’d produce two pages on something that could be said in a couple of sentences.” Nevertheless, his Adderall-assisted papers usually earned him at least a B. They got the job done. As Alex put it, “Productivity is a good thing.”

Last April, the scientific journal Nature published the results of an informal online poll asking whether readers attempted to sharpen “their focus, concentration, or memory” by taking drugs such as Ritalin and Provigil—a newer kind of stimulant, known generically as modafinil, which was developed to treat narcolepsy.

One out of five respondents said that they did. A majority of the fourteen hundred readers who responded said that healthy adults should be permitted to take brain boosters for nonmedical reasons, and sixty-nine per cent said that mild side effects were an acceptable risk. Though a majority said that such drugs should not be made available to children who had no diagnosed medical condition, a third admitted that they would feel pressure to give “smart drugs” to their kids if they learned that other parents were doing so.

Such competitive anxieties are already being felt in the workplace. Recently, an advice column in Wired featured a question from a reader worried about “a rising star at the firm” who was “using unprescribed modafinil to work crazy hours. Our boss has started getting on my case for not being as productive.”

And on Internet forums such as ImmInst, whose members share a nerdy passion for tweaking their cognitive function through drugs and supplements, people trade advice about dosages and “stacks”—improvised combinations—of neuroenhancers. (“Cut a tablet into fourths and took 25 mg every four hours, 4 times today, and had a great and productive day—with no side effects.”)

In one recent post, a fifty-two-year-old—who was working full time, studying for an advanced degree at night, and “married, etc.”—wrote that after experimenting with modafinil he had settled on two daily doses of a hundred milligrams each. He believed that he was “performing a little better,” adding, “I also feel slightly more animated when in discussion.”

Not long ago, I met with Anjan Chatterjee, a neurologist at the University of Pennsylvania, in his office, which is tucked inside the labyrinthine Penn hospital complex. Chatterjee’s main research interests are in subjects like the neurological basis of spatial understanding, but in the past few years, as he has heard more about students taking cognitive enhancers, he has begun writing about the ethical implications of such behavior.

In 2004, he coined the term “cosmetic neurology” to describe the practice of using drugs developed for recognized medical conditions to strengthen ordinary cognition. Chatterjee worries about cosmetic neurology, but he thinks that it will eventually become as acceptable as cosmetic surgery has; in fact, with neuroenhancement it’s harder to argue that it’s frivolous. As he notes in a 2007 paper, “Many sectors of society have winner-take-all conditions in which small advantages produce disproportionate rewards.” At school and at work, the usefulness of being “smarter,” needing less sleep, and learning more quickly are all “abundantly clear.”

In the near future, he predicts, some neurologists will refashion themselves as “quality-of-life consultants,” whose role will be “to provide information while abrogating final responsibility for these decisions to patients.”

The demand is certainly there: from an aging population that won’t put up with memory loss; from overwrought parents bent on giving their children every possible edge; from anxious employees in an efficiency-obsessed, BlackBerry-equipped office culture, where work never really ends.

Chatterjee told me that many people who come to his clinic are cognitively preoccupied versions of what doctors call the “worried well.”

The day I visited his office, he had just seen a middle-aged woman, a successful Philadelphia lawyer, who mentioned having to struggle a bit to come up with certain names. “Here’s an example of someone who by most measures is doing perfectly fine,” Chatterjee said. “She’s not having any trouble at work. But she notices she’s having some problems, and it’s very hard to know how much of that is just getting older.”

Of course, people in her position could strive to get regular exercise and plenty of intellectual stimulation, both of which have been shown to help maintain cognitive function. But maybe they’re already doing so and want a bigger mental rev-up, or maybe they want something easier than sweaty workouts and Russian novels: a pill.

Recently, I spoke on the phone with Barbara Sahakian, a clinical neuropsychologist at Cambridge University, and the co-author of a December, 2007, article in Nature, “Professor’s Little Helper.” Sahakian, who also consults for several pharmaceutical companies, and her co-author, Sharon Morein-Zamir, reported that a number of their colleagues were using prescription drugs like Adderall and Provigil. Because the drugs are easy to buy online, they wrote, it would be difficult to stop their spread:

“The drive for self-enhancement of cognition is likely to be as strong if not stronger than in the realms of ‘enhancement’ of beauty and sexual function.” (In places like Cambridge, at least.)

When I spoke with Sahakian, she had just flown from England to Scottsdale, Arizona, to attend a conference, and she was tired. She might, justifiably, have forgone distractions like me, but she had her cell phone with her, and though it was a weekend morning some industrious person in the Cambridge news office had reached Sahakian in her hotel room, after she got out of the shower and before she had to rush to the first session.

“We may be healthy and high-functioning, and think of ourselves that way, but it’s very rare that we are actually functioning at our optimal level,” Sahakian said. “Take me. I’m over here, and I’ve got jet lag and I’ve got to give a talk tonight and perform well, in what will be the middle of the night, U.K. time.” She mentioned businessmen who have to fly back and forth across the Atlantic: “The difference between making a deal and not is huge and they sometimes only have one meeting to try and do it.” She sympathized with them, but, she added, “we are a society that so wants a quick fix that many people are happy to take drugs.”

For the moment, people looking for that particular quick fix have a limited choice of meds. But, given the amount of money and research hours being spent on developing drugs to treat cognitive decline, Provigil and Adderall are likely to be joined by a bigger pharmacopoeia.

Among the drugs in the pipeline are ampakines, which target a type of glutamate receptor in the brain; it is hoped that they may stem the memory loss associated with diseases like Alzheimer’s. But ampakines may also give healthy people a palpable cognitive boost.

A 2007 study of sixteen healthy elderly volunteers found that five hundred milligrams of one particular ampakine “unequivocally” improved short-term memory, though it appeared to detract from episodic memory—the recall of past events.

Another class of drugs, cholinesterase inhibitors, which are already being used with some success to treat Alzheimer’s patients, have also shown promise as neuroenhancers. In one study, the drug donepezil strengthened the performance of pilots on flight simulators; in another, of thirty healthy young male volunteers, it improved verbal and visual episodic memory. Several pharmaceutical companies are working on drugs that target nicotine receptors in the brain, in the hope that they can replicate the cognitive uptick that smokers get from cigarettes.

Zack and Casey Lynch are a young couple who, in 2005, launched NeuroInsights, a company that advises investors on developments in brain-science technology. (Since then, they’ve also founded a lobbying group, the Neurotechnology Industry Organization.)

Casey and Zack met as undergraduates at U.C.L.A.; she went on to get a master’s degree in neuroscience at U.C.S.F., and he became an executive at a software company.

Last summer, I had coffee with them in the Noe Valley neighborhood of San Francisco, and they both spoke with casual certainty about the coming market for neuroenhancers. Zack, who has a book being published this summer, called “The Neuro Revolution,” said, “We live in an information society. What’s the next form of human society? The neuro-society.” In coming years, he said, scientists will understand the brain better, and we’ll have improved neuroenhancers that some people will use therapeutically, others because they are “on the borderline of needing them therapeutically,” and others purely “for competitive advantage.”

Zack explained that he didn’t really like the term “enhancement”: “We’re not talking about superhuman intelligence. No one’s saying we’re coming out with a pill that’s going to make you smarter than Einstein! . . . What we’re really talking about is enabling people.” He sketched a bell curve on the back of a napkin.

“Almost every drug in development is something that will take someone who’s working at, like, forty per cent or fifty per cent, and take them up to eighty,” he said.

New psychiatric drugs have a way of creating markets for themselves.

Disorders often become widely diagnosed after drugs come along that can alter a set of suboptimal behaviors. In this way, Ritalin and Adderall helped make A.D.H.D. a household name, and advertisements for antidepressants have helped define shyness as a malady.

If there’s a pill that can clear up the wavering focus of sleep-deprived youth, or mitigate the tip-of-the-tongue experience of middle age, then those rather ordinary states may come to be seen as syndromes. As Casey put it, “The drugs get better, and the markets become bigger.”

“Yes,” Zack said. “We call it the lifestyle-improvement market.”

The Lynches said that Provigil was a classic example of a related phenomenon: mission creep.

In 1998, Cephalon, the pharmaceutical company that manufactures it, received government approval to market the drug, but only for “excessive daytime sleepiness” due to narcolepsy; by 2004, Cephalon had obtained permission to expand the labelling, so that it included sleep apnea and “shift-work sleep disorder.” Net sales of Provigil climbed from a hundred and ninety-six million dollars in 2002 to nine hundred and eighty-eight million in 2008.

Cephalon executives have repeatedly said that they do not condone off-label use of Provigil, but in 2002 the company was reprimanded by the F.D.A. for distributing marketing materials that presented the drug as a remedy for tiredness, “decreased activity,” and other supposed ailments. And in 2008 Cephalon paid four hundred and twenty-five million dollars and pleaded guilty to a federal criminal charge relating to its promotion of off-label uses for Provigil and two other drugs.

Later this year, Cephalon plans to introduce Nuvigil, a longer-lasting variant of Provigil.

Candace Steele, a spokesperson, said, “We’re exploring its possibilities to treat excessive sleepiness associated with schizophrenia, bipolar depression, traumatic injury, and jet lag.” Though she emphasized that Cephalon was not developing Nuvigil as a neuroenhancer, she noted, “As part of the preparation for some of these other diseases, we’re looking to see if there’s improvement in cognition.”

Unlike many hypothetical scenarios that bioethicists worry about—human clones, “designer babies”—cognitive enhancement is already in full swing. Even if today’s smart drugs aren’t as powerful as such drugs may someday be, there are plenty of questions that need to be asked about them. How much do they actually help? Are they potentially harmful or addictive? Then, there’s the question of what we mean by “smarter.” Could enhancing one kind of thinking exact a toll on others?

All these questions need proper scientific answers, but for now much of the discussion is taking place furtively, among the increasing number of Americans who are performing daily experiments on their own brains.

Paul Phillips was unusual for a professional poker player.

When he joined the circuit, in the late nineties, he was already a millionaire: a twenty-something tech guy who had started off writing software, helped found an Internet portal called go2net, and cashed in at the right moment.

He was cerebral and, at times, brusque. His nickname was Dot Com.

On the international poker-tournament scene—where the male players tend to be either unabashedly schlumpy or sharply dressed in the manner of a Vegas hotel manager—Phillips cultivated a geeky New Wave style. He wore vintage shirts in wild geometric patterns; his hair was dyed orange or silver one week, shaved off the next. Most unusual of all, Phillips talked freely about taking prescription drugs—Adderall and, especially, Provigil—in order to play better cards.

Buy generic Provigil (Modalert)

He first took up the game in 1995, when he was in college, at U.C. San Diego. He recalled, “It was very mathematical, but you could also inject yourself into the game and manipulate the other guy with words”—more so than in a game like chess.

Phillips soon felt that he had mastered the strategic aspects of poker. The key variable was execution.

At tournaments, he needed to be able to stay focussed for fourteen hours at a stretch, often for several days, but he found it difficult to do so.

In 2003, a doctor gave him a diagnosis of A.D.H.D., and he began taking Adderall. Within six months, he had won $1.6 million at poker events—far more than he’d won in the previous four years. Adderall not only helped him concentrate; it also helped him resist the impulse to keep playing losing hands out of boredom.

In 2004, Phillips asked his doctor to give him a prescription for Provigil, which he added to his Adderall regimen. He took between two hundred and three hundred milligrams of Provigil a day, which, he felt, helped him settle into an even more serene and objective state of mindfulness; as he put it, he felt “less like a participant than an observer—and a very effective one.” Though Phillips sees neuroenhancers as essentially steroids for the brain, they haven’t yet been banned from poker competitions.

Last summer, I visited Phillips in the high-desert resort town of Bend, Oregon, where he lives with his wife, Kathleen, and their two daughters, Ivy and Ruby.

Phillips, who is now thirty-six, seemed a bit out of place in Bend, where people spend a lot of time skiing and river rafting. Among the friendly, faithfully recycling locals, he was making an effort to curb his caustic side. Still, when I first sent Phillips an e-mail asking him to explain, more precisely, how Provigil affected him, he couldn’t resist a smart-ass answer: “More precisely: after a pill is consumed, tiny molecules are absorbed into the bloodstream, where they eventually cross the blood-brain barrier and influence the operation of the wetware up top.”

In person, he was more obliging. He picked me up at the Bend airport driving a black convertible BMW, and we went for coffee at a cheery café called Thump. Phillips wore shorts and flip-flops and his black T-shirt displayed an obscure programming joke.

“Poker is about sitting in one place, watching your opponents for a long time, and making better observations about them than they make about you,” he said.

With Provigil, he “could process all the information about what was going on at the table and do something about it.”

Though there is no question that Phillips became much more successful at poker after taking neuroenhancers, I asked him if his improvement could be explained by a placebo effect, or by coincidence.

He doubted it, but allowed that it could. Still, he said, “there’s a sort of clarity I get with Provigil. With Adderall, I’d characterize the effect as correction—correction of an underlying condition. Provigil feels like enhancement.” And, whereas Adderall made him “jittery,” Provigil’s effects were “completely limited to my brain.” He had “zero difficulty sleeping.”

On the other hand, Phillips said, Provigil’s effects “have attenuated over time. The body is an amazing adjusting machine, and there’s no upside that I’ve been able to see to just taking more.”

A few years ago, Phillips tired of poker, and started playing competitive Scrabble. He was good, but not that good. He was older than many of his rivals, and he needed to undertake a lot of rote memorization, which didn’t come as easily as it once had.

“I stopped short of memorizing the entire dictionary, and to be really good you have to get up to eight- and nine-letter words,” he told me. “But I did learn every word up to five letters, plus maybe ten thousand seven- and eight-letter words.” Provigil, he said, helped with the memorization process, but “it’s not going to make you smarter. It’s going to make you better able to use the tools you have for a sustained period.”

Similarly, a journalist I know, who takes the drug when he has to stay up all night on deadline, says that it doesn’t help in the phase when he’s trying to figure out what he wants to say or how to structure a story; but, once he’s arrived at those insights, it helps him stay intent on completing a draft.

Similarly, a seventy-four-year-old who published a letter in Nature last year offered a charmingly specific description of his modafinil habit: “Previously, I could work competently on the fracture-mechanics of high-silica stone (while replicating ancient tool-flaking techniques) for about an hour. With modafinil, I could continue for almost three hours.”

Cephalon, the Provigil manufacturer, has publicly downplayed the idea that the drug can be used as a smart pill.

In 2007, the company’s founder and C.E.O., Frank Baldino, Jr., told a reporter from the trade journal Pharmaceutical Executive, “I think if you’re tired, Provigil will keep you awake. If you’re not tired, it’s not going to do anything.” But Baldino may have been overly modest. Only a few studies have been done of Provigil’s effects on healthy, non-sleep-deprived volunteers, but those studies suggest that Provigil does provide an edge, at least for some kinds of challenges.

In 2002, researchers at Cambridge University gave sixty healthy young male volunteers a battery of standard cognitive tests. One group received modafinil; the other got a placebo.

The modafinil group performed better on several tasks, such as the “digit span” test, in which subjects are asked to repeat increasingly longer strings of numbers forward, then backward. They also did better in recognizing repeated visual patterns and on a spatial-planning challenge known as the Tower of London task. (It’s not nearly as fun as it sounds.)

Writing in the journal Psychopharmacology, the study’s authors said the results suggested that “modafinil offers significant potential as a cognitive enhancer.”

Phillips told me that, much as he believes in neuroenhancers, he did not want to be “the poster boy for smart-in-a-pill.” At one point, he said, “We really don’t know the possible implications for long-term use of these things.” (He recently stopped taking Provigil every day, replacing it with another prescription stimulant.) He found the “arms-race aspect” of cognitive enhancement distasteful, and didn’t like the idea that parents might force their kids to take smart pills.

He sighed when I suggested that adults, too, might feel coerced into using the drugs.

“Yeah, in a competitive field—if suddenly a quarter of the people are more equipped, but you don’t want to take the risks with your body—it could begin to seem terribly unfair,” he said. “I don’t think we need to be turning up the crank another notch on how hard we work. But the fact is, the baseline competitive level is going to reorient around what these drugs make possible, and you can choose to compete or not.”

In the afternoon, we drove over to Phillips’s house—a big place, handsome and new, with a sweeping deck overhanging the Deschutes River.

Inside, toys were strewn across the shag carpeting. Phillips was waiting for his wife and daughters to come home from the swimming pool, and, sitting in his huge, high-ceilinged living room, he looked a little bored. He told me that he had recently decided to apply to graduate school in computer programming. It was going to be hard—getting out all those applications, convincing graduate programs that he was serious about returning to school. But he had, as he put it, “exhausted myself on all forms of leisure,” and felt nostalgic for his last two years of college, when he had discovered computer programming.

“That was the most purely intellectually satisfying period of my whole life,” he said. “It transformed my brain from being all over the place to a reasonable edifice of knowledge about something.” Back then, he hadn’t taken any smart pills. “I would have been a freakin’ dynamo in college if I’d been taking them,” he said. “But, still, I had to find computers. That made a bigger difference than anything else—finding something I just couldn’t get enough of.”

Provigil may well confer a temporary advantage on healthy people, but this doesn’t mean that it’s ready to replace your morning espresso.

Anjan Chatterjee told me that there “just aren’t enough studies of these drugs in normal people.” He said, “In the situations where they do help, do they come with a cost?”

As he wrote in a recent letter to Nature, “Most seasoned physicians have had the sobering experience of prescribing medications that, despite good intentions, caused bad outcomes.” Given that cognitive enhancement is a choice, not a necessity, the cost-benefit calculation for neuroenhancers should probably be different than it is for, say, heart medications.

Provigil can be habit-forming. In a study published recently in the Journal of the American Medical Association, a group led by Nora Volkow, the director of the National Institute on Drug Abuse, scanned the brains of ten men after they had been given a placebo, and also after they had been given a dose of modafinil. The modafinil appeared to lead to an increase in the brain chemical dopamine. “Because drugs that increase dopamine have the potential for abuse,” Volkow’s report concluded, “these results suggest that risk for addiction in vulnerable persons merits heightened awareness.” (Cephalon, in a response to the report, notes that Provigil’s label urges physicians to monitor patients closely, especially those with a history of drug abuse.)

On the Web site Erowid, where people vividly, and anonymously, report their experiences with legal and illegal drugs, some modafinil users have described a dependency on the drug.

One man, who identified himself as a former biochemistry student, said that he had succeeded in kicking cocaine and opiate habits but couldn’t stop using modafinil. Whenever he ran out of the drug, he said, “I start to freak out.” After “4-5 days” without it, “the head fog starts to come back.”

Eliminating foggy-headedness seems to be the goal of many users of neuroenhancers. But can today’s drugs actually accomplish this?

I recently posed this question to Anjan Chatterjee’s colleague Martha Farah, who is a psychologist at Penn and the director of its Center for Cognitive Neuroscience.

She has been writing about neuroenhancers for several years from a perspective that is deeply fascinated and mildly critical, but basically in favor—with the important caveat that we need to know much more about how these drugs work.

I spoke with her one afternoon at her research center, which is in a decidedly unfuturistic-looking Victorian house on Walnut Street, in Philadelphia.

Farah, who is an energetic conversationalist, had bought canned espresso drinks for us. Though she does not take neuroenhancers, she has found that her interest in them has renewed her romance with the next best thing: caffeine.

Farah had just finished a paper in which she reviewed the evidence on prescription stimulants as neuroenhancers from forty laboratory studies involving healthy subjects.

Most of the studies looked at one of three types of cognition: learning, working memory, and cognitive control.

A typical learning test asks subjects to memorize a list of paired words; an hour, a few days, or a week later, they are presented with the first words in the pairs and asked to come up with the second. The studies on learning showed that neuroenhancers did improve retention. The benefits were more apparent in studies where subjects had been asked to remember information for several days or longer.

Working memory has been likened to a mental scratch pad: you use it to keep relevant data in mind while you’re completing a task. (Imagine a cross-examination, in which a lawyer has to keep track of the answers a witness has given, and formulate new questions based on them.)

In one common test, subjects are shown a series of items—usually letters or numbers—and then presented with challenges: Was this number or letter in the series? Was this one? In the working-memory tests, subjects performed better on neuroenhancers, though several of the studies suggested that the effect depended on how good a subject’s working memory was to begin with: the better it was, the less benefit the drugs provided.

The third category that the studies examined was cognitive control—how effectively you can check yourself in circumstances where the most natural response is the wrong one. A classic test is the Stroop Task, in which people are shown the name of a color (let’s say orange) written in a different color (let’s say purple). They’re asked to read the word (which is easy, because our habitual response to a word is to read it) or to name the ink color (which is harder, because our first impulse is to say “orange”). These studies presented a more mixed picture, but over all they showed some benefit “for most normal healthy subjects”—especially for people who had inherently poorer cognitive control.

Farah told me, “These drugs will definitely help some technically normal people—that is, people who don’t meet the diagnostic criteria for A.D.H.D. or any kind of cognitive impairment.” But, she emphasized, “they will help people in the lower end of the ability range more than in the higher end.”

One explanation for this phenomenon might be that, the more adept you are at a given task, the less room you have to improve. Farah has a hunch that there may be another reason that existing drugs, so far, at least, don’t offer as much help to people with greater intellectual abilities.

Drugs like Ritalin and Adderall work, in part, by elevating the amount of dopamine in the brain. Dopamine is something you want just enough of: too little, and you may not be as alert and motivated as you need to be; too much, and you may feel overstimulated.

Neuroscientists have discovered that some people have a gene that leads the brain to break down dopamine faster, leaving less of it available; such people are generally a little worse at certain cognitive tasks. People with more available dopamine are generally somewhat better at the same tasks. It makes sense, then, that people with naturally low dopamine would benefit more from an artificial boost.

Of course, learning, working memory, and cognitive control represent just a few aspects of thinking. Farah concluded that studies looking at other kinds of cognition—verbal fluency, for instance—were too few and too contradictory to tell us much. And the effects of neuroenhancers on some vital forms of intellectual activity, such as abstract thought and creativity, have barely been studied at all. Farah said that the extant literature was concerned with “fairly boring kinds of thinking—how long can you stay vigilant while staring at a screen and waiting for a little light to blink.” She added, “It would be great to have studies of more flexible kinds of thought.”

Both Chatterjee and Farah have wondered whether drugs that heighten users’ focus might dampen their creativity. After all, some of our best ideas come to us not when we sit down at a desk but, rather, when we’re in the shower or walking the dog—letting our minds roam.

Jimi Hendrix reported that the inspiration for “Purple Haze” came to him in a dream; the chemist Friedrich August Kekule claimed that he discovered the ring structure of benzene during a reverie in which he saw the image of a snake biting its tail. Farah told me, “Cognitive psychologists have found that there is a trade-off between attentional focus and creativity. And there is some evidence that suggests that individuals who are better able to focus on one thing and filter out distractions tend to be less creative.”

Farah and Chatterjee recently completed a preliminary study looking at the effect of one ten-milligram dose of Adderall on sixteen students doing standard laboratory tests of creative thinking. They did not find that this low dose had a detrimental effect, but both believe that this is only the beginning of the vetting that must be done.

“More and more of our young people are using these drugs to help them work,” Farah said. “They’ve got their laptop, their iPhone, and their Adderall. This rising generation of workers and leaders may have a subtly different style of thinking and working, because they’re using these drugs or because they learned to work using these drugs, so that even if you take the drugs away they’ll still have a certain approach. I’m a little concerned that we could be raising a generation of very focussed accountants.”

Farah has also been considering the ethical complications resulting from the rise of smart drugs.

Don’t neuroenhancers confer yet another advantage on the kind of people who already can afford private tutors and prep courses? At many colleges, students have begun calling the off-label use of neuroenhancers a form of cheating.

Writing last year in the Cavalier Daily, the student newspaper of the University of Virginia, a columnist named Greg Crapanzano argued that neuroenhancers “create an unfair advantage for the users who are willing to break the law in order to gain an edge. These students create work that is dependent on the use of a pill rather than their own work ethic.”

Of course, it’s hard to imagine a university administration that would require students to pee in a cup before they get their blue books. And though secretly taking a neuroenhancer for a three-hour exam does seem unfair, condemning the drugs’ use seems extreme. Even with the aid of a neuroenhancer, you still have to write the essay, conceive the screenplay, or finish the grant proposal, and if you can take credit for work you’ve done on caffeine or nicotine, then you can take credit for work produced on Provigil.

Farah questions the idea that neuroenhancers will expand inequality. Citing the “pretty clear trend across the studies that say neuroenhancers will be less helpful for people who score above average,” she said that cognitive-enhancing pills could actually become levellers, if they are dispensed cheaply.

A 2007 discussion paper published by the British Medical Association also makes this point: “Equality of opportunity is an explicit goal of our education system, giving individuals the best chance of achieving their full potential and of competing on equal terms with their peers. Selective use of neuroenhancers amongst those with lower intellectual capacity, or those from deprived backgrounds who do not have the benefit of additional tuition, could enhance the educational opportunities for those groups.”

If the idea of giving a pill as a substitute for better teaching seems repellent—like substituting an I.V. drip of synthetic nutrition for actual food—it may nevertheless be preferable to a scenario in which only wealthy kids receive a frequent mental boost.

Farah was one of several scholars who contributed to a recent article in Nature, “Towards Responsible Use of Cognitive Enhancing Drugs by the Healthy.”

The optimistic tone of the article suggested that some bioethicists are leaning toward endorsing neuroenhancement. “Like all new technologies, cognitive enhancement can be used well or poorly,” the article declared. “We should welcome new methods of improving our brain function.

In a world in which human workspans and lifespans are increasing, cognitive enhancement tools—including the pharmacological—will be increasingly useful for improved quality of life and extended work productivity, as well as to stave off normal and pathological age-related cognitive declines. Safe and effective cognitive enhancers will benefit both the individual and society.”

The British Medical Association report offered a similarly upbeat observation: “Universal access to enhancing interventions would bring up the base-line level of cognitive ability, which is generally seen to be a good thing.”

And yet when enthusiasts share their vision of our neuroenhanced future it can sound dystopian.

Zack Lynch, of NeuroInsights, gave me a rationale for smart pills that I found particularly grim.

“If you’re a fifty-five-year-old in Boston, you have to compete with a twenty-six-year-old from Mumbai now, and those kinds of pressures are only going to grow,” he began. Countries other than the U.S. might tend to be a little looser with their regulations, and offer approval of new cognitive enhancers first. “And if you’re a company that’s got forty-seven offices worldwide, and all of a sudden your Singapore office is using cognitive enablers, and you’re saying to Congress, ‘I’m moving all my financial operations to Singapore and Taiwan, because it’s legal to use those there,’ you bet that Congress is going to say, ‘Well, O.K.’ It will be a moot question then. It would be like saying, ‘No, you can’t use a cell phone. It might increase productivity!’ ”

If we eventually decide that neuroenhancers work, and are basically safe, will we one day enforce their use?

Lawmakers might compel certain workers—emergency-room doctors, air-traffic controllers—to take them. (Indeed, the Air Force already makes modafinil available to pilots embarking on long missions.)

For the rest of us, the pressure will be subtler—that queasy feeling I get when I remember that my younger colleague is taking Provigil to meet deadlines. All this may be leading to a kind of society I’m not sure I want to live in: a society where we’re even more overworked and driven by technology than we already are, and where we have to take drugs to keep up; a society where we give children academic steroids along with their daily vitamins.

Paul McHugh, a psychiatrist at Johns Hopkins University, has written skeptically about cosmetic neurology. In a 2004 essay, he notes that at least once a year in his private practice he sees a young person—usually a boy—whose parents worry that his school performance could be better, and want a medication that will assure it.

In most of these cases, “the truth is that the son does not have the superior I.Q. of his parents,” though the boy may have other qualities that surpass those of his parents—he may be “handsome, charming, athletic, graceful.” McHugh sees his job as trying to get the parents to “forget about adjusting him to their aims with medication or anything else.”

When I spoke with him on the phone, McHugh expanded on this point: “Maybe it’s wrong-footed trying to fit people into the world, rather than trying to make the world a better place for people. And if the idea is that the only college your child can go to is Harvard, well, maybe that’s the idea that needs righting.”

If Alex, the Harvard student, and Paul Phillips, the poker player, consider their use of neuroenhancers a private act, Nicholas Seltzer sees his habit as a pursuit that aligns him with a larger movement for improving humanity.

Seltzer has a B.A. from U.C. Davis and a master’s degree in security policy from George Washington University. But the job that he obtained with these credentials—as a researcher at a defense-oriented think tank, in northern Virginia—has not left him feeling as intellectually alive as he would like.

To compensate, he writes papers in his spare time on subjects like “human biological evolution and warfare.” He also primes his brain with artificial challenges; even when he goes to the rest room at the office, he takes the opportunity to play memory or logic games on his cell phone.

Seltzer, who is thirty, told me that he worried that he “didn’t have the mental energy, the endurance, the—I don’t know what to properly call this—the sponginess that I seem to recall having when I was younger.”

Suffice it to say that this is not something you notice when you talk to Seltzer. And though our memory is probably at its peak in our early twenties, few thirty-year-olds are aware of a deficit.

But Seltzer is the Washington-wonk equivalent of those models and actors in L.A. who discern tiny wrinkles long before their agent does.

His girlfriend, a technology consultant whom he met in a museum, is nine years younger, and he was already thinking about how his mental fitness would stand up next to hers. He told me, “She’s twenty-one, and I want to stay young and vigorous and don’t want to be a burden on her later in life.” He didn’t worry about visible signs of aging, but he wanted to keep his mind “nimble and healthy for as long as possible.”

Seltzer considers himself a “transhumanist,” in the mold of the Oxford philosopher Nick Bostrom and the futurist writer and inventor Ray Kurzweil.

Transhumanists are interested in robots, cryogenics, and living a really, really long time; they consider biological limitations that the rest of us might accept, or even appreciate, as creaky obstacles to be aggressively surmounted.

On the ImmInst forums—“ImmInst” stands for “Immortality Institute”—Seltzer and other members discuss life-extension strategies and the potential benefits of cognitive enhancers. Some of the forum members limit themselves to vitamin and mineral supplements. Others use Adderall or modafinil or, like Seltzer, a drug called piracetam, which was first marketed by a Belgian pharmaceutical company in 1972 and, in recent years, has become available in the U.S. from retailers that sell supplements.

Although not approved for any use by the F.D.A., piracetam has been used experimentally on stroke patients—to little effect—and on patients with a rare neurological condition called progressive myoclonus epilepsy, for whom it proved helpful in alleviating muscle spasms. Data on piracetam’s benefits for healthy people are virtually nonexistent, but many users believe that the drug increases blood flow to the brain.

From the time I first talked to Seltzer, it was clear that although he felt cognitive enhancers were of practical use, they also appealed to him on an aesthetic level.

Using neuroenhancers, he said, “is like customizing yourself—customizing your brain.” For some people, he went on, it was important to enhance their mood, so they took antidepressants; but for people like him it was more important “to increase mental horsepower.” He added, “It’s fundamentally a choice you’re making about how you want to experience consciousness.” Whereas the nineties had been about “the personalization of technology,” this decade was about the personalization of the brain—what some enthusiasts have begun to call “mind hacking.”

Of course, the idea behind mind-hacking isn’t exactly new. Fortifying one’s mental stamina with drugs of various kinds has a long history.

Sir Francis Bacon consumed everything from tobacco to saffron in the hope of goosing his brain.

Balzac reputedly fuelled sixteen-hour bouts of writing with copious servings of coffee, which, he wrote, “chases away sleep, and gives us the capacity to engage a little longer in the exercise of our intellects.”

Sartre dosed himself with speed in order to finish “Critique of Dialectical Reason.”

My college friends and I wrote term papers with the sweaty-palmed assistance of NoDoz tablets. And, before smoking bans, entire office cultures chugged along on a collective nicotine buzz—at least, if “Mad Men” is to be believed.

Seltzer and his interlocutors on the ImmInst forum are just the latest members of a seasoned cohort, even if they have more complex pharmaceuticals at their disposal.

I eventually met Seltzer in an underground food court not far from the Pentagon. We sat down at a Formica table in the dim light. Seltzer was slim, had a shaved head, and wore metal-frame glasses; matching his fastidious look, he spoke precisely, rarely stumbling over his words.

I asked him if he had any ethical worries about smart drugs. After a pause, he said that he might have a concern if somebody popped a neuroenhancer before taking a licensing exam that certified him as, say, a brain surgeon, and then stopped using the drug.

Other than that, he couldn’t see a problem. He said that he was a firm believer in the idea that “we should have a fair degree of liberty to do with our bodies and our minds as we see fit, so long as it doesn’t impinge on the basic rights, liberty, and safety of others.” He argued, “Why would you want an upward limit on the intellectual capabilities of a human being? And, if you have a very nationalist viewpoint, why wouldn’t you want our country to have the advantage over other countries, particularly in what some people call a knowledge-based economy?”

He went on, “Think about the complexity of the intellectual tasks that people need to accomplish today. Just trying to understand what Congress is doing is not a simple thing! The complexity of understanding the gamut of scientific and technical and social issues is difficult. If we had a tool that enabled more people to understand the world at a greater level of sophistication, how can we prejudice ourselves against the notion, simply because we don’t like athletes to do it? To me, it doesn’t seem like the same question. And it deserves its own debate.”

Seltzer had never had a diagnosis of any kind of learning disorder. But he added, “Though I wouldn’t say I’m dyslexic, sometimes when I type prose, after I look back and read it, I’ve frequently left out words or interposed words, and sometimes I have difficulty concentrating.”

In graduate school, he obtained a prescription for Adderall from a doctor who didn’t ask a lot of questions. The drug helped him, especially when his ambitions were relatively low. He recalled, “I had this one paper, on nuclear strategy. The professor didn’t look favorably on any kind of creative thinking.” On Adderall, he pumped out the paper in an evening. “I just bit my tongue, regurgitated, and got a good-enough grade.”

On the other hand, Seltzer recalled that he had taken piracetam to write an essay on “the idea of harmony as a trope in Chinese political discourse”—it was one of the papers he was proudest of. He said, “It was really an intellectual challenge to do. I felt that the piracetam helped me to work within the realm of the abstract, and make the kind of associations that I needed—following this idea of harmony from an ancient religious belief as it was translated throughout the centuries into a very important topic in political discourse.”

After a hiatus of several years, Seltzer had recently resumed taking neuroenhancers. In addition to piracetam, he took a stack of supplements that he thought helped his brain functioning: fish oils, five antioxidants, a product called ChocoMind, and a number of others, all available at the health-food store.

He was thinking about adding modafinil, but hadn’t yet. For breakfast every morning, he concocted a slurry of oatmeal, berries, soy milk, pomegranate juice, flaxseed, almond meal, raw eggs, and protein powder. The goal behind the recipe was efficiency: to rely on “one goop you could eat or drink that would have everything you need nutritionally for your brain and body.”

He explained, “Taste was the last thing on my mind; I wanted to be able to keep it down—that was it.” (He told me this in the kitchen of his apartment; he lives with a roommate, who walked in while we were talking, listened perplexedly for a moment, then put a frozen pizza in the oven.)

Seltzer’s decision to take piracetam was based on his own online reading, which included medical-journal abstracts.

He hadn’t consulted a doctor. Since settling on a daily regimen of supplements, he had sensed an improvement in his intellectual work and his ability to engage in stimulating conversation. He continued, “I feel I’m better able to articulate my thoughts. I’m sure you’ve been in the zone—you’re having a really exciting debate with somebody, your brain feels alive. I feel that more. But I don’t want to say that it’s this profound change.”

I asked him if piracetam made him feel smarter, or just more alert and confident—a little better equipped to marshal the resources he naturally had. “Maybe,” he said. “I’m not sure what being smarter means, entirely. It’s a difficult quality to measure. It’s the gestalt factor, all these qualities coming together—not only your ability to crunch some numbers, or remember some figures or a sequence of numbers, but also your ability to maintain a certain emotional state that is conducive to productive intellectual work. I do feel I’m more intelligent with the drugs, but I can’t give you a number of I.Q. points.”

The effects of piracetam on healthy volunteers have been studied even less than those of Adderall or modafinil. Most peer-reviewed studies focus on its effects on dementia, or on people who have suffered a seizure or a concussion.

Many of the studies that look at other neurological effects were performed on rats and mice. Piracetam’s mechanisms of action are not understood, though it may increase levels of the neurotransmitter acetylcholine.

In 2008, a committee of the British Academy of Medical Sciences noted that many of the clinical trials of piracetam for dementia were methodologically flawed. Another published review of the available studies of the drug concluded that the evidence “does not support the use of piracetam in the treatment of people with dementia or cognitive impairment,” but suggested that further investigation might be warranted. I asked Seltzer if he thought he should wait for scientific ratification of piracetam. He laughed. “I don’t want to,” he said. “Because it’s working.”

It makes no sense to ban the use of neuroenhancers. Too many people are already taking them, and the users tend to be educated and privileged people who proceed with just enough caution to avoid getting into trouble.

Besides, Anjan Chatterjee is right that there is an apt analogy with plastic surgery. In a consumer society like ours, if people are properly informed about the risks and benefits of neuroenhancers, they can make their own choices about how to alter their minds, just as they can make their own decisions about shaping their bodies.

Still, even if you acknowledge that cosmetic neurology is here to stay, there is something dispiriting about the way the drugs are used—the kind of aspirations they open up, or don’t. Jonathan Eisen, an evolutionary biologist at U.C. Davis, is skeptical of what he mockingly calls “brain doping.” During a recent conversation, he spoke about colleagues who take neuroenhancers in order to grind out grant proposals. “It’s weird to me that people are taking these drugs to write grants,” he said. “I mean, if you came up with some really interesting paper that was spurred by taking some really interesting drug—magic mushrooms or something—that would make more sense to me. In the end, you’re only as good as the ideas you’ve come up with.”

But it’s not the mind-expanding sixties anymore. Every era, it seems, has its own defining drug. Neuroenhancers are perfectly suited for the anxiety of white-collar competition in a floundering economy. And they have a synergistic relationship with our multiplying digital technologies: the more gadgets we own, the more distracted we become, and the more we need help in order to focus.

The experience that neuroenhancement offers is not, for the most part, about opening the doors of perception, or about breaking the bonds of the self, or about experiencing a surge of genius. It’s about squeezing out an extra few hours to finish those sales figures when you’d really rather collapse into bed; getting a B instead of a B-minus on the final exam in a lecture class where you spent half your time texting; cramming for the G.R.E.s at night, because the information-industry job you got after college turned out to be deadening. Neuroenhancers don’t offer freedom. Rather, they facilitate a pinched, unromantic, grindingly efficient form of productivity.

This winter, I spoke again with Alex, the Harvard graduate, and found that, after a break of several months, he had gone back to taking Adderall—a small dose every day. He felt that he was learning to use the drug in a more “disciplined” manner. Now, he said, it was less about staying up late to finish work he should have done earlier, and more “about staying focussed on work, which makes me want to work longer hours.” What employer would object to that?

by Margaret Talbot

http://www.newyorker.com

But what if taking one little pill could give you the boost and focus you need to get everything done, without ever losing steam?

Just how smart are these new types of “smart drugs?“

David Plotz was exhausted. His had just had his first child. He was swamped at work.

So when he began working on a story for online magazine, slate, about living without sleep, he jumped at the chance to try a medication for narcolepsy called Provigil.

“The drug, it was a revelation because I had this whole day, this whole 16 hours with none of the down time that you have. You’re always on. I felt like I was my best self all the time,“ said Plotz.

Provigil is part of a class of drugs called cognitive enhancers.

It includes popular attention deficit disorder medications, Ritalin and Adderall.

These drugs are said to improve memory, concentration and learning.

One study predicts that over the next few decades, drug makers will develop nearly 600 new types of these drugs.

“Provigil is a yuppy drug. It doesn’t give you a high. It doesn’t make you feel ecstatic. All it does is make it easier for you to work harder,“ said Plotz

Dr. Nora Volkow from the National Institute on Drug Abuse says more and more healthy adults are using these drugs off label to help them be more productive at work, school and home even though they are only FDA approved for actual medical problems, like a-d-d and narcolepsy.

“What is concerning to me right now is the high levels that these medications are being already utilized by healthy individuals out there, when we don’t have sufficient information about their benefits and we don’t have a lot of information about the adverse effects,“ said Volkow.

Cognitive enhancers work by altering the amount of neurotransmitters in the brain.

That basically stimulates the mind.

It can make boring tasks seem interesting.

There’s some evidence showing these drugs can help healthy people.

But Volkow says the possible side effects often outweigh the benefits.

Some people do experience improved focus and productivity.

But once they’re off the drug, they may be less productive than they were before they started using the medication.

And for others, it can be dangerous.

“Some of these medications with high doses can produce psychotic reactions, can produce paranoia or full blown psychosis,“ Volkow said.

David Plotz, who is now slate’s editor, says he did not experience any side effects.

He says he still takes Provigil on occasion, if he has an overwhelming workload or long a drive ahead of him.

But he is concerned about safety:
There are no long term studies on Provigil, so we really don’t know what it’s doing to the brain.

These medicines only available by prescription – you should not try to use them without a doctor’s supervision.

http://www.counton2.com

Unfortunately, the weight gain commonly experienced with antipsychotic treatment is an important side effect for many patients, and causes many patients to discontinue their use leading to even further problems.

Biological Psychiatry, in its April 1st issue, is now publishing a new study that has evaluated an add-on treatment to potentially reduce treatment-associated weight gain.

In a randomized, double-blind, placebo-controlled trial, Dr. James Roerig and colleagues evaluated the effect of modafinil on olanzapine-associated weight gain in normal volunteer subjects.

Modafinil is a drug currently used to increase wakefulness in individuals with sleep disorders, such as narcolepsy.

All of the subjects received olanzapine, and half also received modafinil treatment while the other half instead received placebo. After three weeks, although the body mass index was increased in both groups, those receiving olanzapine/placebo showed significantly greater weight increase than those receiving olanzapine/modafinil.

Dr. Roerig notes that now that this short-term study in healthy individuals has shown promise, modafinil can now be evaluated as a “viable candidate for a larger, more complex clinical trial to determine efficacy in a patient population.”

Dr. John Krystal, Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, agrees that further research is warranted. “Psychiatrists are now working more closely with patients to manage the side effects of antipsychotic treatment. The finding that modafinil reduces weight gain may encourage more research to see whether there are other benefits associated with modafinil prescription with regards to symptoms or cognitive impairments associated with schizophrenia.”

Elsevier
http://www.elsevier.com

Democratic lawmakers have talked about passing legislation to outlaw such deals, and President Barack Obama has vowed to stop the deals in his budget. A House Energy and Commerce subcommittee is holding a hearing Tuesday on the issue.

The savings to the health-care system from eliminating such agreements, which are sometimes referred to as “pay to go away,” would be significant. Generic drugs can cost as little as a quarter of the price of their brand-name cousins, saving billions of dollars a year in drug costs. The deals can also set the stage for further delays in generic drugs coming to market.

Ten brand-name drugs with about $17 billion in annual U.S. sales are now protected by the agreements, said Scott Hemphill, an associate professor at Columbia Law School, a critic of the deals. The drugs include such blockbusters as Pfizer Inc.’s cholesterol drug Lipitor, he said.

Pfizer said the Lipitor deal didn’t contain any of the practices that have been of concern to the Federal Trade Commission, and the deal gave consumers earlier access to a generic version than they might have otherwise received.

Drug companies have successfully argued in court cases that their patents allow them to make the deals. They also say the deals boost their profits and help them invest in new medicines.

The FTC has fought the payments for years. In its latest effort, the FTC filed a lawsuit in February 2008 against Cephalon Inc., of Frazer, Pa. It alleged Cephalon broke antitrust law by making more than $200 million in payments and inducements to four companies to delay their introduction of generic versions of Provigil, Cephalon’s lucrative narcolepsy drug, for six years until 2012.

After the deals were struck, Cephalon Chief Executive Frank Baldino Jr. told the Philadelphia Business Journal the company got “six more years of patent protection. That’s $4 billion in sales that no one expected.”

Cephalon said the deals were legal and will actually give patients early access to generic Provigil, because all its patents on the drug don’t expire until 2015. But it also acknowledges using the time before generic Provigil goes on sale to shift patients to a longer-acting version of the wakefulness drug, with a patent running until 2023.

The FTC has filed six suits since 2001 to block deals involving payments by drug companies to generic makers, but it has encountered little success in the courts.

In an interview, FTC Chairman Jon Leibowitz said stopping the arrangements is an agency priority. The deals enrich drug companies, he said, while “consumers are left holding the bag.”

In Congress, Sen. Herb Kohl, a Wisconsin Democrat, has proposed a bill barring the deals, and a similar bill was introduced in the House last week by Rep. Bobby L. Rush, an Illinois Democrat.

Similar legislation, including a 2007 measure that Mr. Obama co-sponsored as a senator, has failed in the past. A White House spokesman wouldn’t comment on whether the president will support such legislation this year.

Even if the agreements are ever banned in court or by Congress, companies may have already found a way to game it. Ronny Gal, an analyst at Sanford C. Bernstein & Co., pointed to the settlement of a patent dispute earlier this month between Medicis Pharmaceutical Corp. and Teva Pharmaceutical Industries Ltd. as a potential model.

Teva had begun selling generic versions of a Medicis acne drug before legal disputes over the patent were resolved. Under a settlement, Teva agreed to halt further sales of the generic until 2011, but was allowed to keep revenue from the products it had already sold.

Mr. Gal estimated Teva earned $25 million from its sale of generic copies of the drug, and said it didn’t get a payment from Medicis to resolve the dispute. “This could simply be a wink-and-a-nod way of getting the same amount of money,” he said. Teva and Medicis declined to comment.

http://online.wsj.com/article/SB123843757514670479.html

Apparently, offender numbers have shown a marked rise over the last four years even though according to the governments own board of expert advisors, cannabis use has dropped since it was intially declassified to a class C substance back in 2004. Confused?

According to the government, this rise in offences is due to how the police were able to deal with people found in possession of cannabis under the new class C category. Which begs the question; what difference does that make exactly?

Of course the real reason cannabis enforcement is higher than it has been for many years is as a result of the public relations campaign the government have undertaken in the run up to the ill-advised reclassification which took place in January of 2009.

Lets face it if you influence a nations press to write about wellington boots every day for two years at the end of the campaign wellington boot sales are going to be showing a healthy up-turn. Its not called public relations for nothing. Just ask Julie Myerson.

So its fair to assume with all of the news coverage regarding prescription drugs such as narcolepsy treatment Provigil and ADD treatment Ritalin, its fair to assume the same thing is going to happen. The numbers of people who are using these drugs, (and who are finding themselves in trouble for doing so illegally, or ‘off-label’ as our American cousins quaintly like to call it) is going to increase.

At the top of the pile currently is the anti-narcoleptic Provigil, made by US pharmaceutical giant Cephalon. A company which employs around 3000 employees and is said to be worth just under $5 billion US dollars, and on a personal note its worth mentioning I didn’t even know what Provigil was until two weeks ago, and now I really want some.

Cephalon has been in the news recently regarding a number of patent disputes, after a number of smaller pharma’s decided to create their own versions of Cephalon’s brain drug Provigil (generic name Modafinil).

In 2003 Cephalon took a number of these drug companies to court over patent infringements. Surprisingly Cephalon was unsuccessful and had to negotiate outside of the courts. In a bid to recoup some of their losses from Modafinil, Cephalon instigated a number of licensing deals to cover future manufacture of a drug which was being marketed so aggressively even the US military was buying it in by the container load in a bid to keep its exhausted fighter pilots in the air.

From this point forth the marketing ‘focus’ was moved from being an anti-narcoleptic, to being a “stay awake” mood brightener, and in 2007 the company was hit with an intoxicating fine of $425 million dollars for illegal marketing practices relating to off-label promotion of modafinil, (there’s that term ‘off-label’ again).

Today Provigil/Modafinil continues to dominate the prescription drug news, and for a number of different reasons.

On the one hand we hear of students, doctors, truck drivers etc. Anyone in fact who works long hours or night-shifts, visiting their doctor and asking for Provigil for their ‘narcolepsy’. Apparently all it takes is a straight face while you ask for it, and your wish is my command. Or rather your doctors command.

Provigil/Modafinil is being prescribed by the truck load, and even the driver of the truck delivering it is most-likely on Provigil too.

But the whole distasteful saga has taken something a sinister turn of late.

From being hailed as a wonder drug on its creation, it now appears all of those students and truckers merrily crunching Provigil tic-tacs in between chain-drinking cups of espresso, may be getting addicted.

To a drug which was supposed not to affect the part of the brain involved in the reward-chain? How does that work?

The big marketing angle for Provigil was the fact it tip-toed around the brains dopamine receptors, where as other stimulants such as Methylphenidate, AKA hard-assed amphetamine based ADD/ADHD treatment Ritalin, stamped all over the dopamine receptors with hobnail boots on, giving the user the uncomfortable ‘crash landing’ as they came down off their 48 hour drug-induced stay-awake-athon.

Anyone who has overdosed on strong coffee whilst going without sleep will know the feeling of getting ‘the jitters’ all too well.

But now it appears all that good news which was released on the initial release of provigil, could well have been wrong. So much for clinical trials.

But not to worry, because as luck would have Cephalon is about to bring a new, safer drug to market, called Nuvigil, and at this stage if you can see a pattern forming here, have another cup of coffee to reward yourself, and read on.

Nuvigil, (generic name Amodafinil) is a new flavour of Provigil which received FDA aproval in the US on June 15th 2007, and before rushing out to buy yourself a chemistry set and knocking up your own version, Cephalon have secured this patent until 2023 so don’t even go there.

Apparently Amodafinil is a ’stimulant-like’ drug which is being aimed as a treatment for bi-polar depression, conditions associated with schizophrenia, as well as chronic fatigue syndrome associated with Parkinsons disease and MS, amongst a great many others.

Far be it for me, a simple truck driver with very red eyes to point fingers, but I do find it something of a coincidence that with a new drug to find a market for, all of a sudden the super-safe Provigil, is no longer super-safe. Far from it in fact, and a quick ‘Google’ will turn up all sorts of ‘if’s buts and maybes’s’, without actually telling us the information we need.

Is Provigil dangerous and addictive, or is it not?

The truth of the matter is, it doesn’t matter.

There has been so much news coverage regarding Provigil, a drug which generates around $500 million US every year, that its markets are safe. If this wasn’t the case there would be no illicit heroin market lets face it?

But the real issue here, is the readiness of the worlds press to undertake global marketing and publicity for a product which is by its creators own admission, unsafe, as they can’t tell the public whether they will become addicted or not. Only that they might, (or might not).

Little wonder then, that the world is currently in the teeth of a prescription drug epidemic which grows exponentially year on year, and there’s not a thing we can do about it.

In the meantime, we have hard and fast evidence regarding a cure for a large number of cancers, which the press simply refuse to cover, and the government won’t let us have access to, even though the drug in question has never been credibly linked to a single death..ever.

There’s no doubting the pharmaceutical industry does a fantastic job in improving the quality of life for many millions of people every single year. But the fact their products are readily available on a million websites, and to absolutely anyone who has access to a credit card number is no accident.

Even worse is the fact government’s seem ill-prepared to anything about this, whilst in the meantime sending over-zealous police forces in to kick peoples doors down simply for growing a cannabis plant or two.

Something’s just not right about it all and I can’t quite put my finger on it.

Provigil-RX.Info

A new study from the Montreal Neurological Institute (MNI) at McGill University demonstrates interestingly, that sleep-wake states are regulated by two different types of nerve cells (neurons), melanin-concentrating hormone (MCH) neurons and orexin (Orx) neurons, which occupy the same region of the brain but perform opposite functions.

The MNI study is the first to discover that MCH neurons are activated during sleep and could thus be important in regulating the sleep state. The study, published in this week’s issue of the journal Proceedings of the National Academy of Sciences (PNAS), provides deeper understanding of the sleep-wake cycle and vital insight into the basis of sleep disorders such as narcolepsy and possibly also other diseases such as depression and Parkinson’s.

Sleep is regulated by processes in the brain in response to how long we are awake in addition to the light/dark cycle controlled by the circadian rhythm.

With Drs. Oum Hassani and Maan Gee Lee, Dr. Barbara Jones at the MNI were studying a structure in the brain called the lateral hypothalamus (LH) known to be critical for maintaining wakefulness.

MCH neurons, co-distributed with Orx neurons, constitute less than 10% of the LH.

Previous studies have shown that Orx neurons are essential for maintenance of the awake state. These neurons are active in the waking state and turn off during sleep and in their absence, animals and humans experience narcolepsy with cataplexy or sudden loss of muscle tone.

However, the role of MCH neurons was until now, unclear. Evidence from earlier knockout studies suggested that MCH neurons might play a different role than Orx neurons in regulating activity and sleep-wake states.

Therefore the team at the MNI set up experiments to study the function of MCH neurons during the sleep-wake states.

“Remarkably, what we found is that MCH neurons are actually silent during waking, which is a surprising finding especially in this wake-promoting region of the brain.

The neurons fire during sleep, and are most active during REM sleep,” says Dr. Barbara Jones, neuroscientist at the MNI and principal investigator in the study. “Our study markedly demonstrates that MCH neurons discharge in a reciprocal manner to the Orx neurons across the sleep-wake cycle.”

Dr. Jones and colleagues used their expertise to apply and develop a difficult technique which allowed them to selectively record, label and thus identify a nerve cell containing a particular chemical. This allowed them to isolate the functions of the MCH and Orx cells even though they comprise less than 10% of the nerve cells in the LH.

The reciprocal profiles and roles of the Orx and MCH neurons could be significant in the manifestation of sleep disorders.

It is possible that narcolepsy, which occurs with the loss of Orx neurons, is provoked in part by the MCH neurons that remain intact in the narcoleptic patients. A growing body of research shows that regular and normal sleep is necessary for overall health; regulating hormone levels, blood pressure, metabolism, alertness, mood, and consolidating memory.

This study presents potential therapeutic avenues and targets for the treatment of various sleep disorders including the development of drugs that will act on receptors for Orx and MCH, to stimulate or block these receptors accordingly.

(Source: McGill University: Proceedings of the National Academy of Sciences: March 2009)

http://www.virtualmedicalcentre.com

A pilot study on 10 healthy men found that at normal doses, the Cephalon Inc (CEPH.O) drug known generically as modafinil increases levels of the reward chemical dopamine in the same part of the brain that becomes active with other drugs of abuse.

“It has the signature that it could potentially be addictive,” said Dr. Nora Volkow, director of the National Institute on Drug Abuse, whose study appears in the Journal of the American Medical Association.

“Studies have shown consistently that all of the drugs of abuse … have a common effect of increasing dopamine in this area, in the nucleus accumbens,” Volkow said in a telephone interview.

“That is believed to be crucial for their reinforcing effect and ultimately their underlying potential for producing addiction.”

Cephalon said in a statement the findings are consistent with what is already known about the drug, noting that it is classified as a schedule IV medication by the Drug Enforcement Administration, meaning it has some potential for abuse and dependence.

While officially approved only for excess sleepiness associated with narcolepsy, sleep apnea, and shift work disorder, Provigil is also used for weight loss, attention deficit hyperactivity disorder, fatigue and depression. Last year, it had sales of more than $852 million.

But its increasing use on college campuses to improve cognitive performance led Volkow to look more closely at the drug’s potential for addiction and abuse.

“The main problems that we see are not the people who are properly prescribed the medication, but individuals who may be misusing and abusing the medication,” Volkow said.

BRAIN-BOOSTER

In December, Volkow said recent surveys on college campuses suggest drugs such as Novartis’ Ritalin (NOVN.VX), or methylphenidate, and Provigil are being used by students, professors and others as a brain-boosting drug.

Volkow said it had not been clear before the study whether Provigil increases dopamine — the same chemical reward system in the human brain as other drugs of abuse.

The researchers used positron emission tomography and a well-known drug of addiction to trace the activity of modafinil in 10 healthy men between the ages of 23 and 46.

Volkow said the preliminary findings show modafinil activates the dopamine reward system in the brain. “That potential had been dismissed for modafinil because it was believed it had no significant dopinergic effects. Our findings question that,” she said.

“The message for individuals who are taking this medication who want cognitive enhancement is that its use could result in very serious cognitive effects, including addiction.”

Volkow said her agency plans to begin monitoring use of modafinil in its regular surveys of potential drugs of abuse.

http://www.reuters.com